Clinical decision-making should be individualized, considering the patient's complete metabolic profile, disease severity, and treatment goals
GLP-1 medications can help fill that gap, not just by supporting weight loss but by helping rebuild metabolic resilience
In trials involving male patients, researchers in the 2004 trial noted that PT-141 (bremelanotide) was safe and well tolerated in both studies (Rosen et al., 2004) [5]
In addition, there is modulation of signal transduction of the signaling pathways of glycogen synthase kinase 3 (GSK-3), protein kinase C (PKC), mammalian target of rapamycin (mTOR), wingless-related integration site (Wnt), erythroblastic leukemia viral oncogene homolog (ErbB), mitogen-activated protein kinase (MAPK), and vascular endothelial growth factor (VEGF) [1]